Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting

被引：0
|
作者：
B. Muresan
C. Mamolo
J. C. Cappelleri
M. J. Postma
B. Heeg
机构：
[1] Ingress-health Netherlands,Department of Health Sciences, University Medical Center Groningen
[2] Pfizer Inc,Department of Economics, Econometrics and Finance, Faculty of Economics and Business
[3] University of Groningen,undefined
[4] University of Groningen,undefined
来源：
Applied Health Economics and Health Policy | 2021年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：929 / 940
页数：11
相关论文
共 50 条
  • [41] The safety of Bosutinib for the treatment of chronic myeloid leukemia
    Kong, Jee Hyun
    Khoury, H. J.
    Kim, Audrey Sunwha
    Hill, Brittany Gray
    Kota, Vamsi
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (10) : 1203 - 1209
  • [42] Recommendations on monitoring and second-line therapy for chronic myeloid leukemia
    Hochhaus, A.
    Overkamp, F.
    Lange, T.
    Mohr, A.
    Ottmann, O.
    Coutre, P.
    Haferlach, T.
    ONKOLOGE, 2010, 16 (07): : 701 - 708
  • [43] COST-EFFECTIVENESS OF IBRUTINIB AS FRONTLINE TREATMENT FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN BELGIUM
    Smet, A.
    Peng, S.
    Dorman, E.
    Deger, K.
    Sorensen, S.
    Baculae, S.
    Cote, S.
    VALUE IN HEALTH, 2017, 20 (05) : A108 - A108
  • [44] Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib
    Radich, Jerald P.
    Hochhaus, Andreas
    Giles, Francis J.
    Ross, David M.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Kim, Dong-Wook
    Fellague-Chebra, Rafik
    Sondhi, Manu
    Tiwari, Ranjan
    Mishra, Kaushal
    Mahon, Francois-Xavier
    BLOOD, 2019, 134
  • [45] COST-EFFECTIVENESS ANALYSIS OF PONATINIB IN THE TREATMENT OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN SWEDEN
    Iannazzo, S.
    McGarry, L.
    Chiroli, S.
    VALUE IN HEALTH, 2015, 18 (07) : A668 - A668
  • [46] EFFICACY AND SAFETY OF SECOND LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
    Breccia, M.
    Abruzzese, E.
    Castagnetti, F.
    Bonifacio, M.
    Gangemi, D.
    Sora, F.
    Iurlo, A.
    Luciano, L.
    Gozzini, A.
    Gentile, M.
    Bocchia, M.
    Luzi, D.
    Maggi, A.
    Sgherza, N.
    Isidori, A.
    Crugnola, M.
    Pregno, P.
    Foa, R.
    HAEMATOLOGICA, 2017, 102 : 89 - 89
  • [47] Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia
    Hsyu, Poe-Hirr
    Mould, Diane R.
    Upton, Richard N.
    Amantea, Michael
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 209 - 218
  • [48] The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment
    Eskazan, Ahmet Emre
    Soysal, Teoman
    LEUKEMIA & LYMPHOMA, 2015, 56 (05) : 1554 - 1555
  • [49] Second-line Therapy and Beyond Resistance for the Treatment of Patients With Chronic Myeloid Leukemia Post Imatinib Failure
    Jabbour, Elias
    Cortes, Jorge E.
    Kantarjian, Hagop
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S272 - S279
  • [50] Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors
    Cuc Thi Thu Nguyen
    Binh Thanh Nguyen
    Thuy Thi Thu Nguyen
    Fabio Petrelli
    Stefania Scuri
    Iolanda Grappasonni
    Quality of Life Research, 2022, 31 : 733 - 743
12345